Wij zijn onze website aan het vernieuwen.

Ontdekt u nog een pagina die niet klopt of hebt u een goede suggestie, laat het ons dan weten via webmedia@umcutrecht.nl.

Deze website maakt gebruik van cookies

Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Lees meer over het cookiebeleid.

Cardiovascular Regenerative Medicine

Cardiovascular regenerative medicine integrates research (both basic and applied) and patient care for regenerative medicine. We explore strategies to enhance efficacy, including potent cell types, cell less cell therapy approaches (e.g. miRNA, exosomes treatment), the smart use of biomaterials, and novel delivery strategies using state-of-the-art image fusion.


The translational axis drives our work. To this end, we utilize the abundant experience of the UU animal facility with a strong collaboration between the Hubrecht lab and the TU/e (Technical University, Eindhoven, NL). This creates an effective cross-pollination between the strategic programs of the UMC Utrecht namely Circulatory Health and Regenerative Medicine.

Our Research

Our research is translational in nature, covering the range from basic research to clinical trials. Our studies include many areas from novel treatments for kidney damage using stem cells, to developing smart biomaterials that stimulate the bodies regeneration of defective heart valves, and the use of innovative imaging techniques in chorus with advanced echocardiography and histology/ bio banking of bone marrow, skin, artery and veins with the ultimate aim of restoring areas around the border of damaged sites, to name a few. In preclinical trials potency of cell therapy (e.g. cardiomyocyte progenitor cells, induced pluripotent stem cells) and other regenerative approaches are tested. We encouraged our research teams to participate in multicenter clinical trials (PRECISE, HEBE, LUMCU-HF), and initiate such trials as PI (e.g. JUVENTAS, AMICI, RIPASSA).

The stakes are high, as are expectations, yet our discipline takes tremendous time, effort, invention and patience to advance with expected high quality research. While the going can be slow at times, each movement brings us a step closer to the discoveries of new frontiers in medicine.

Our research focuses on:

  • preclinical trials in acute and chronic ischemic heart disease
  • (multicenter) clinical trials with autologous and allogeneic cell sources
  • state-of-the-art imaging techniques

Key publications

  • Similar Effect of Autologous and Allogeneic Cell Therapy for Ischemic Heart Disease: Systematic Review and Meta-Analysis of Large Animal Studies. Jansen Of Lorkeers SJ1, Eding JE1, Vesterinen HM2, van der Spoel TI1, Sena ES2, Duckers HJ1, Doevendans PA1, Macleod MR2, Chamuleau SA3. Circ Res. 2014 Sep 3. Epub ahead of print].
  • Inhibition of miR-25 improves cardiac contractility in the failing heart. Wahlquist C1, Jeong D2, Rojas-Muñoz A3, Kho C4, Lee A4, Mitsuyama S4, van Mil A5, Park WJ6, Sluijter JP7, Doevendans PA7, Hajjar RJ4, Mercola M3. Nature. 2014 Apr 24;508(7497):531-5.
  • Placebo in Autologous Cell-Based Interventions: Hard Pill to Swallow? Koudstaal S, Niemansburg SL, Dib N, Wallet J, Doevendans PA, Bredenoord AL, Chamuleau SA. J Am Coll Cardiol. 2014 Apr 18. pii: S0735-1097(14)02070-1.
  • Sustained delivery of insulin-like growth factor-1/hepatocyte growth factor stimulates endogenous cardiac repair in the chronic infarcted pig heart. Koudstaal S1, Bastings MM, Feyen DA, Waring CD, van Slochteren FJ, Dankers PY, Torella D, Sluijter JP, Nadal-Ginard B, Doevendans PA, Ellison GM, Chamuleau SA. J Cardiovasc Transl Res. 2014 Mar;7(2):232-41
  • Bone marrow microvascular and neuropathic alterations in patients with critical limb ischemia. Teraa M1, Fledderus JO, Rozbeh RI, Leguit RJ, Verhaar MC; Juventas Study Group{dagger}. Circ Res. 2014 Jan 17;114(2):311-4.
  • Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Hirsch A1, Nijveldt R, van der Vleuten PA, Tijssen JG, van der Giessen WJ, Tio RA, Waltenberger J, ten Berg JM, Doevendans PA, Aengevaeren WR, Zwaginga JJ, Biemond BJ, van Rossum AC, Piek JJ, Zijlstra F; HEBE Investigators. Eur Heart J. 2011 Jul;32(14):1736-47
  • Improvement of mouse cardiac function by hESC-derived cardiomyocytes correlates with vascularity but not graft size. van Laake LW1, Passier R, den Ouden K, Schreurs C, Monshouwer-Kloots J, Ward-van Oostwaard D, van Echteld CJ, Doevendans PA, Mummery CL. Stem Cell Res. 2009 Sep-Nov;3(2-3):106-12.

Principal investigator(s)

Coordinator

S.A.J. Chamuleau


PI's

G.J. de Borst, L.W. van Laake, J.P.G. Sluijter, M.C. Verhaar.

To top